|
TPSC-w
|
Cell cycle and mitotic process (G1, G12)
|
HTLV-I infection and Prostate cancer (G1)
|
3p21.3 and 8p12-p11 (G1)
|
| | |
P53 signaling, PI3K-AKt signaling and FOXO signaling pathway (G12)
|
7q21.3, 1q32 and 17q22-q23 (G12)
|
| | | |
17q11.2(G1, G12)
|
|
TPSC-1
|
Extracellular matrix and structure organization, blood vessel development, cell adhesion and motility (M6)
|
Extracellular matrix organization, collagen formation and ensemble of genes encoding ECM-associated proteins (M6)
|
11q22.3 and 13q34 (M6)
|
| |
Response to growth hormone (M16)
|
Pathways related to RHO GTPases (M21, M23)
|
17q11.2 and 6q22-q23 (M16)
|
| |
Cell cycle and mitotic process (M21, M23)
|
Proteoglycans in cancer and circadian clock (M21)
|
1p32 (M23)
|
| | |
Antifolate resistance (M23)
| |
|
WGCNA
|
Cell cycle and mitotic process (W2)
|
P53 signaling, oocyte meiosis and PI3K-AKt infection (W2)
|
20q11.2 and 12q13.12 (W2)
|
| |
Activation of T cell, lymphocyte and leukocyte (W13)
|
Cytokine, NF-Kappa B, chemokine and TNF signaling(W13)
|
1q31-q32, 1p36 and 1q23 (W13)
|
|
lmQCM
|
Cell cycle and mitotic process(Q4)
|
RHO GTPases pathways, P53 pathways, oocyte meiosis and HTLV-I infection (Q4)
|
12q13.12, 2p24.2, 15q15.1 and 4q27(Q4)
|
| |
Epithelial cell development and mammary gland development (Q7)
|
ERBB2- and ERBB4-related signaling (Q7)
|
4q31.21 and 1p33(Q7)
|
